Q3 2024 Earnings Call Transcript November 7, 2024 MannKind Corporation beats earnings expectations. Reported EPS is $0.05, ...

MannKind will host a conference call and presentation webcast to discuss these results today at 4:30 p.m. Eastern Time. The webcast will be accessible via a link on MannKind’s website. A replay will ...

Shares of MannKind Co. (NASDAQ:MNKD – Get Free Report) have received a consensus recommendation of “Buy” from the seven ...

MannKind Corporation ( (MNKD) ) has released its Q3 earnings. Here is a breakdown of the information MannKind Corporation presented to its ...

Good Afternoon and welcome to the Mannkind Corporation third quarter, 2024 financial results earnings call. As a reminder, this call is being recorded on November 7, 2024. And we'll be available ...

MannKind completes phase 1 trial of nintedanib DPI for pulmonary fibrotic diseases: Danbury, Connecticut Tuesday, November 5, 2024, 16:00 Hrs [IST] MannKind Corporation, a company ...

Waters new software delivers lab-centric business intelligence and enables confident audit-readiness: Our Bureau, Bengaluru Tuesday, November 12, 2024, 09:00 Hrs [IST] Waters Corp ...

Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ETCompany ParticipantsMichael Castagna - CEOChris Prentiss ...

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the quarter ended September 30, 2024.

Met primary objective demonstrating nintedanib DPI was safe and well toleratedParticipants did not experience adverse events typically reported with oral nintedanibExpect to meet with the FDA in 1H ...